What RPG Life Sciences does

RPG Life Sciences Limited is a publicly listed Indian pharmaceutical company and part of the RPG Group conglomerate, founded in 1968 and headquartered in Mumbai. The company operates as an integrated pharmaceutical firm across three business verticals: Active Pharmaceutical Ingredients (APIs), Domestic Formulations, and International Formulations. It manufactures synthetic APIs at a facility in Navi Mumbai (which experienced a fire incident in January 2025 and has since recovered) and finished formulations at a facility in Ankleshwar, Gujarat. Its product portfolio spans more than ten therapeutic areas including Nephrology, Oncology, Urology, Cardiovascular, Anti-Diabetic, Orthopedic, Rheumatology, Respiratory, Gastroenterology, Gynaecology and Pediatrics, Neurology, Anti-Dengue, and Dermatology, with a stated leadership position in immunosuppressants.

The company's business model is B2B and B2B2C in nature, generating revenue through branded formulations sold across the Indian domestic market (via field sales and standard pharma distribution), generic formulations exported to international markets, and APIs sold to global pharmaceutical manufacturers. For FY26, the company reported net sales of Rs 707.52 crore, up 8.28% year-over-year, with Q4 FY26 revenue growing 23.6% to Rs 176.89 crore and a Q4 EBITDA margin of 25.6%. Management has set explicit revenue targets of Rs 1,000 crore by 2028 and Rs 2,500 crore by 2030, and has committed Rs 600-1,000 crore for API acquisitions targeting niche complex molecules. The company is led by Managing Director Ashok Nair (with Vishal Shah as CFO) and trades on NSE and BSE with a market capitalization of approximately Rs 3,724.92 crore as of April 2026.

Name

RPG Life Sciences

Legal name

RPG Life Sciences Limited

Website

https://rpglifesciences.com

Company type

Public

Founded year

1968

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

RPG Life Sciences is a publicly listed Indian pharmaceutical company operating across three verticals — synthetic APIs, domestic branded formulations, and international generic formulations — serving patients and global drug manufacturers across 10+ therapeutic areas with a leadership position in immunosuppressants.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

Keywords

• Active pharmaceutical ingredients
• Branded formulations
• Generic pharmaceuticals
• Immunosuppressant medications
• API manufacturing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Domestic Formulations: Branded formulations sold in the Indian domestic market, delivering market-beating growth of 18.2% versus the Indian Pharma Market's 10.1% growth in Q4 FY26
2. International Formulations: Generic formulations sold in international markets
3. Active Pharmaceutical Ingredients (API): API business recovering strongly with 144.3% growth in Q4 FY26 following recovery from fire incident at manufacturing plant. The company plans to scale through acquisitions worth Rs 600-1,000 crore targeting niche, complex molecules

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Core offering

RPG Life Sciences is an integrated pharmaceutical company that manufactures and supplies Active Pharmaceutical Ingredients (APIs) and finished dosage formulations across more than 10 therapeutic areas. It operates three business verticals — APIs (synthetic molecules including immunosuppressants, antipsychotics, and pain management), Domestic Formulations (branded medicines in the Indian market), and International Formulations (generic formulations for global markets) — supported by API manufacturing in Navi Mumbai and formulations manufacturing in Ankleshwar, Gujarat.

Product overview

RPG Life Sciences is an integrated pharmaceutical company operating through three business verticals: Active Pharmaceutical Ingredients (API), Domestic Formulations, and International Formulations. The company operates formulations manufacturing facilities at Ankleshwar, Gujarat and a synthetic API facility at Navi Mumbai. Their formulations portfolio spans over 10 therapeutic areas including Nephrology, Oncology, Urology, Cardiovascular, Anti-Diabetic, Orthopedic, Respiratory, Gastroenterology, Rheumatology, Gynaecology and Pediatrics, Vitamins and Minerals, Neurology, Anti-Dengue, and Dermatology. The company positions itself as leaders in immunosuppressants within the global pharmaceutical market.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (API) Synthetic Active Pharmaceutical Ingredients manufactured for global pharmaceutical manufacturers, targeting niche molecules in immunosuppressants, antipsychotics, and pain management. Produced at the company's synthetic API facility in Navi Mumbai.
• Domestic Formulations Branded pharmaceutical formulations sold within the Indian domestic market across more than 10 therapeutic areas including Nephrology, Cardiovascular, Anti-Diabetic, Orthopedic, Urology, Oncology, Rheumatology, Gastroenterology, Respiratory, Gynaecology and Pediatrics, Vitamins and Minerals, Neurology, Anti-Dengue, and Dermatology. Manufactured at the Ankleshwar, Gujarat facility.
• International Formulations Generic pharmaceutical formulations exported to international markets, complementing the company's domestic formulations business and API manufacturing capabilities.
• T-Jaki Pharmaceutical formulation product in the RPG Life Sciences portfolio.
• Aldactone T Pharmaceutical formulation product in the RPG Life Sciences portfolio.
• Romilast BL Pharmaceutical formulation product in the RPG Life Sciences portfolio.
• Neosez Pharmaceutical formulation product in the RPG Life Sciences portfolio.
• Rivorca Pharmaceutical formulation product in the RPG Life Sciences portfolio.
• Bulalfa Pharmaceutical formulation product in the RPG Life Sciences portfolio.

Quantifiable outcome

• Q4 FY26 revenue growth of 23.6% YoY to Rs 176.90 crore
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators14 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Torrent Pharmaceuticals: Mid-to-large Indian pharma company focused on branded generics domestically with selective international presence. Comparable therapeutic mix (cardiovascular, CNS, gastroenterology) and similar API-plus-formulations vertical integration.
• Alkem Laboratories: Indian pharmaceutical manufacturer with anti-infective, cardiovascular, and chronic therapy focus. Comparable branded formulations distribution model in India with growing international generics exposure.
• Glenmark Pharmaceuticals: Indian pharma company with branded generics, APIs, and specialty/innovative drug development. Overlaps RPG in respiratory, dermatology, and cardiovascular segments with comparable India-focused sales force model.
• Cadila Healthcare (Zydus): Larger Indian pharmaceutical group with broader portfolio across APIs, biosimilars, generics, and consumer health. Competes in many of RPG's therapeutic areas but operates at significantly greater scale with established US FDA infrastructure.

Direct peers

• Ipca Laboratories: API-centric Indian pharmaceutical company with domestic and international formulations. Comparable in API manufacturing scale and therapeutic focus areas including anti-malarial, pain management, and cardiovascular, with similar niche molecule strategy.
• Cipla: One of India's largest pharmaceutical companies with a directly comparable model: integrated API plus formulations, strong domestic franchise, and international generic exports. Overlaps RPG in therapeutic areas including respiratory, cardiovascular, and specialty segments.
• Aurobindo Pharma: Major Indian API and formulations manufacturer with substantial US generics presence. Highly comparable vertically integrated model and aggressive inorganic growth strategy targeting complex molecules, similar to RPG's stated acquisition approach.
• Lupin: Indian pharma company operating across formulations, APIs, and specialty segments with direct overlap in cardiovascular, anti-diabetic, and respiratory therapies. Comparable integrated API-plus-formulations business model targeting both Indian and regulated markets.
• Dr. Reddy's Laboratories: Integrated Indian pharma major with global generics, API manufacturing, and branded formulations in India. Comparable revenue mix and therapeutic breadth, particularly in oncology, cardiovascular, and gastroenterology where RPG competes.

Emerging players

• Ajanta Pharma: Mid-sized Indian pharma company with branded domestic formulations and emerging international generics business. Comparable scale and therapeutic focus in chronic and specialty segments; potential target for the kind of inorganic consolidation RPG is pursuing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/rpg-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RPG Life Sciences